Cancer Care Center of Southern Indiana

Bloomington, Indiana 47403

0 studies enrolling now · 17 studies all time

What they study most

Bladder Carcinoma, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Non-Hodgkin, Melanoma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Transitional Cell Carcinoma

Studies at this site

• First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma — Stopped early
• Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer — Completed
• Sutent + Taxol for Advanced Esophageal Cancer — Completed
• Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer — Stopped early
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma — Stopped early
• Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer — Completed
• A Biological Sample Collection Protocol of Women With and Without Breast Cancer — Completed
• Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer — Stopped early
• Lonafarnib in Metastatic Breast Cancer — Stopped early
• Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas — Stopped early
• Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer — Completed
• Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies — Completed
• A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer — Stopped early
• Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer — Completed
• STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma — Completed
• A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer — Completed
• Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer — Stopped early